Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021)
- PMID: 36571281
- DOI: 10.1093/ajhp/zxac381
Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021)
Abstract
Purpose: Antithrombotic agents have a role in coronavirus disease 2019 (COVID-19) treatment, but the pandemic disrupted medication supply. This study examined changes in the volume of oral and parenteral anticoagulant and antiplatelet medications at US hospitals during the pandemic.
Methods: IQVIA National Sales Perspective (NSP) data was used to determine the monthly volume of anticoagulants and antiplatelets purchased at US hospitals between January 2018 and February 2021. Mean monthly medication volumes, reported as extended units (EUs), and year-over-year changes in medication volume were determined. A single-group interrupted time series analysis was used to evaluate changes in the rate of growth of monthly medication volumes before (January 2019-February 2020) and during (March 2020-February 2021) the COVID-19 pandemic.
Results: Overall, there was a 43.4% decline in the total volume of anticoagulants and antiplatelets at US hospitals in March 2020, driven by a decrease in heparin volume. Mean monthly volumes decreased significantly (P < 0.05) for parenteral anticoagulants (-106,691,340 EU [95% CI, -200,033,910 to -13,348,780]), oral anticoagulants (-354,800 EU [95% CI, -612,180 to -97,420]), and parenteral antiplatelets (-391,880 EU [95% CI, -535,420 to -248,330]). During the pandemic, the monthly volume of oral anticoagulants, parenteral anticoagulants, and parenteral antiplatelets grew significantly more than in the prepandemic period. This growth was primarily seen in volumes of apixaban, argatroban, enoxaparin, heparin, eptifibatide, and tirofiban. Apixaban and heparin volumes continued a prepandemic uptrend, while argatroban and eptifibatide volumes reversed trend.
Conclusion: Rapid changes in anticoagulant and antiplatelet volume at US hospitals during the COVID-19 pandemic highlight the need for institutional protocols to manage fluctuating medication volume demands.
Keywords: COVID-19; anticoagulants; antiplatelet drugs; hospital pharmacy service.
© American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.Drug Alcohol Depend. 2022 Mar 1;232:109291. doi: 10.1016/j.drugalcdep.2022.109291. Epub 2022 Jan 11. Drug Alcohol Depend. 2022. PMID: 35033953 Free PMC article.
-
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).Am J Cardiol. 2005 Jun 1;95(11):1295-301. doi: 10.1016/j.amjcard.2005.01.071. Am J Cardiol. 2005. PMID: 15904632 Clinical Trial.
-
Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.J Am Coll Cardiol. 2004 Mar 17;43(6):966-71. doi: 10.1016/j.jacc.2003.09.060. J Am Coll Cardiol. 2004. PMID: 15028351
-
Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.Drugs. 2002;62(12):1755-70. doi: 10.2165/00003495-200262120-00005. Drugs. 2002. PMID: 12149045 Review.
-
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.J Thromb Thrombolysis. 2001 Apr;11(2):99-110. doi: 10.1023/a:1011216414539. J Thromb Thrombolysis. 2001. PMID: 11406724 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical